Market barriers affect a staggering 39 percent of prescriptions for injectable treatments for Type 2 Diabetes Mellitus in the U.S. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different barriers with any given brand, and for some brands that grows to 3.
Find out which barriers cost your brand the most market share, which competitors are taking it from you, and what you can do to win it back, in Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US).
Based on a survey of 100 diabetologists and primary care physicians, the report covers 11 major injectable therapies from GSK, Novo Nordisk, Sanofi, and Eli Lilly. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.